Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine the feasibility of routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Gender Based Eligibility:
Gender Eligibility Description:
Females with ovarian cancer
Accepts Healthy Volunteers:
new diagnosis of epithelial ovarian, primary peritoneal, fallopian tube or extra- uterine mullerian cancer.
All subjects must have a new diagnosis of epithelial ovarian, primary peritoneal, fallopian tube or extra- uterine mullerian cancer.
All subjects must have either undergone primary surgery or be planning neoadjuvant chemotherapy for the treatment of ovarian, primary peritoneal or fallopian tube cancer.
All subjects must be able to comprehend and communicate in English.
All subjects must agree to participate.
A previous diagnosis of cancer is not an exclusion criterion.
Previous genetic screening is not an exclusion criterion.
Patients who do not meet the above inclusion criteria.
Patients with a diagnosis of a low malignant potential mullerian tumor.
Patients who are not proficient in English language because the survey aspect of this study is comprised of 4 validated surveys that are only available in English language.